Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 194,606 | 210,171 | 179,213 | 327,039 | 276,771 |
| Receivables | 720,915 | 754,207 | 762,221 | 786,980 | 780,375 |
| Inventories | 278,544 | 336,200 | 349,111 | 361,281 | 380,259 |
| Other current assets | 105,796 | 101,514 | 110,836 | 99,054 | 83,378 |
| TOTAL | $1,403,071 | $1,494,723 | $1,499,273 | $1,668,188 | $1,608,662 |
| Non-Current Assets | |||||
| PPE Net | 1,604,014 | 1,639,978 | 1,613,895 | 1,618,708 | 1,639,741 |
| Investments And Advances | 218,350 | 235,987 | 231,859 | 243,543 | 243,811 |
| Intangibles | 3,570,008 | 3,903,053 | 3,879,822 | 3,897,879 | 3,959,096 |
| Other Non-Current Assets | 732,902 | 730,101 | 723,434 | 724,465 | 743,690 |
| TOTAL | $6,125,274 | $6,509,119 | $6,449,010 | $6,484,595 | $6,586,338 |
| Total Assets | $7,528,345 | $8,003,842 | $7,948,283 | $8,152,783 | $8,195,001 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 140,337 | 135,963 | 133,101 | 129,682 | 168,937 |
| Accrued Expenses | 411,428 | 419,201 | 368,823 | 380,498 | 441,115 |
| Other current liabilities | 194,014 | 205,089 | 198,418 | 188,247 | 203,210 |
| TOTAL | $994,101 | $1,012,221 | $947,519 | $954,810 | $1,055,082 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,240,205 | 2,326,653 | 2,409,380 | 2,660,459 | 2,647,147 |
| Deferred Revenues | 248,322 | 251,968 | 247,177 | 256,383 | 241,820 |
| Other Non-Current Liabilities | 720,059 | 709,078 | 698,702 | 709,748 | 697,279 |
| TOTAL | $3,067,292 | $3,204,494 | $3,273,746 | $3,551,823 | $3,537,643 |
| Total Liabilities | $4,061,393 | $4,216,715 | $4,221,265 | $4,506,633 | $4,592,725 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,142 | 51,136 | 51,631 | 51,512 | 51,350 |
| Common Shares | 511 | 517 | 517 | 515 | 513 |
| Retained earnings | 1,812,100 | 2,122,835 | 2,053,557 | 1,959,777 | 1,887,218 |
| Other shareholders' equity | -311,896 | -187,638 | -265,685 | -244,555 | -191,033 |
| TOTAL | $3,466,952 | $3,787,127 | $3,727,018 | $3,646,150 | $3,602,276 |
| Total Liabilities And Equity | $7,528,345 | $8,003,842 | $7,948,283 | $8,152,783 | $8,195,001 |